These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 34395270)

  • 1. Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy.
    Li Y; Zhao L; Li XF
    Front Oncol; 2021; 11():700407. PubMed ID: 34395270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.
    Phillips RM
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):441-57. PubMed ID: 26811177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.
    Guise CP; Mowday AM; Ashoorzadeh A; Yuan R; Lin WH; Wu DH; Smaill JB; Patterson AV; Ding K
    Chin J Cancer; 2014 Feb; 33(2):80-6. PubMed ID: 23845143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Schedule-dependent potentiation of chemotherapy drugs by the hypoxia-activated prodrug SN30000.
    Mao X; McManaway S; Jaiswal JK; Hong CR; Wilson WR; Hicks KO
    Cancer Biol Ther; 2019; 20(9):1258-1269. PubMed ID: 31131698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the therapeutic response of tumors to hypoxia-targeted prodrugs with an in silico approach.
    Yilmaz D; Tuzer M; Unlu MB
    Math Biosci Eng; 2022 Aug; 19(11):10941-10962. PubMed ID: 36124576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study.
    Albertella MR; Loadman PM; Jones PH; Phillips RM; Rampling R; Burnet N; Alcock C; Anthoney A; Vjaters E; Dunk CR; Harris PA; Wong A; Lalani AS; Twelves CJ
    Clin Cancer Res; 2008 Feb; 14(4):1096-104. PubMed ID: 18281542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Hypoxia-Inducible Factor-1α for the Management of Hepatocellular Carcinoma.
    Huynh KN; Rao S; Roth B; Bryan T; Fernando DM; Dayyani F; Imagawa D; Abi-Jaoudeh N
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selectively Potentiating Hypoxia Levels by Combretastatin A4 Nanomedicine: Toward Highly Enhanced Hypoxia-Activated Prodrug Tirapazamine Therapy for Metastatic Tumors.
    Yang S; Tang Z; Hu C; Zhang D; Shen N; Yu H; Chen X
    Adv Mater; 2019 Mar; 31(11):e1805955. PubMed ID: 30680816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy.
    Li Y; Zhao L; Li XF
    Front Pharmacol; 2021; 12():636892. PubMed ID: 33953675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy.
    Mistry IN; Thomas M; Calder EDD; Conway SJ; Hammond EM
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1183-1196. PubMed ID: 28721903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigational Hypoxia-Activated Prodrugs: Making Sense of Future Development.
    Su MX; Zhang LL; Huang ZJ; Shi JJ; Lu JJ
    Curr Drug Targets; 2019; 20(6):668-678. PubMed ID: 30468124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia Activated Prodrugs: Factors Influencing Design and Development.
    Liang D; Miller GH; Tranmer GK
    Curr Med Chem; 2015; 22(37):4313-25. PubMed ID: 26487420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.
    Patterson AV; Ferry DM; Edmunds SJ; Gu Y; Singleton RS; Patel K; Pullen SM; Hicks KO; Syddall SP; Atwell GJ; Yang S; Denny WA; Wilson WR
    Clin Cancer Res; 2007 Jul; 13(13):3922-32. PubMed ID: 17606726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia.
    Wang J; Foehrenbacher A; Su J; Patel R; Hay MP; Hicks KO; Wilson WR
    Clin Cancer Res; 2012 Mar; 18(6):1684-95. PubMed ID: 22167409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting DNA topoisomerase IIα (TOP2A) in the hypoxic tumour microenvironment using unidirectional hypoxia-activated prodrugs (uHAPs).
    Smith PJ; McKeown SR; Patterson LH
    IUBMB Life; 2023 Jan; 75(1):40-54. PubMed ID: 35499745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Model System for Understanding Anticancer Activity of Hypoxia-Activated Prodrugs.
    Sun Z; Zhang H; Wu J; Gao F; Zhang C; Hu X; Liu Q; Wei Y; Zhuang J; Huang X
    Mol Pharm; 2020 Jun; 17(6):2072-2082. PubMed ID: 32352301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs.
    Hunter FW; Wang J; Patel R; Hsu HL; Hickey AJ; Hay MP; Wilson WR
    Biochem Pharmacol; 2012 Mar; 83(5):574-85. PubMed ID: 22182429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deep-learning and MR images to target hypoxic habitats with evofosfamide in preclinical models of sarcoma.
    Jardim-Perassi BV; Mu W; Huang S; Tomaszewski MR; Poleszczuk J; Abdalah MA; Budzevich MM; Dominguez-Viqueira W; Reed DR; Bui MM; Johnson JO; Martinez GV; Gillies RJ
    Theranostics; 2021; 11(11):5313-5329. PubMed ID: 33859749
    [No Abstract]   [Full Text] [Related]  

  • 19. Prospects for hypoxia-activated anticancer drugs.
    Denny WA
    Curr Med Chem Anticancer Agents; 2004 Sep; 4(5):395-9. PubMed ID: 15379691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo Studies.
    Takakusagi Y; Kishimoto S; Naz S; Matsumoto S; Saito K; Hart CP; Mitchell JB; Krishna MC
    Antioxid Redox Signal; 2018 Jan; 28(2):131-140. PubMed ID: 28741367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.